白介素1受体拮抗剂治疗骨关节炎的研究进展  

Research progress of interleukin-1 receptor antagonists in the treatment of osteoarthritis

作　　者：张平全 黄子荣 胡艳 梁宇杰 朱伟民 Zhang Pingquan;Huang Zirong;Hu Yan;Liang Yujie;Zhu Weimin(Clinical College,Shenzhen Second Hospital of Anhui Medical University,Shenzhen Guangdong,518035;Department of Sports Medicine,Shenzhen Second People's Hospital,Shenzhen Guangdong,518035;Shenzhen Kangning Hospital,Shenzhen Guangdong,518020,China)

机构地区：[1]安徽医科大学深圳二院临床学院,广东深圳518035 [2]深圳市第二人民医院运动医学科,广东深圳518035 [3]深圳市康宁医院,广东深圳518020

出　　处：《生物骨科材料与临床研究》2023年第4期80-84,共5页Orthopaedic Biomechanics Materials and Clinical Study

基　　金：深圳市科创委基金(JCYJ20210324102607021)。

摘　　要：骨关节炎(osteoarthritis,OA)是临床治疗中常见的骨科疾病,其主要以关节软骨变形、破坏及骨质增生为特征,目前没有根治手段。已有大量研究证明,白介素1(interleukin-1,IL-1)在OA病理进程中发挥关键作用,而IL-1受体拮抗剂(IL-1 receptor antagonist,IL-1Ra)已被证实可以竞争性地与IL-1受体结合,阻断IL-1的生物活性,从而抑制骨关节炎的进展,为OA治疗提供新的可能。本文将针对IL-1Ra在骨关节炎的治疗研究进展进行综述,围绕IL-1Ra介导的相关通路及其治疗骨关节炎的机理和策略进行总结,为OA治疗的研究和临床开发提供参考。Osteoarthritis(OA)is a common orthopedic disease in clinical treatment,which is mainly characterized by articular cartilage deformation,destruction and bone hyperplasia.Currently,there is no radical treatment.It has been proved that interleukin-1(IL-1)plays an important role in the occurrence and development of osteoarthritis,and IL-1 receptor antagonist(IL-1Ra)has been confirmed to competitively bind to IL-1 receptor and block the biological activity of IL-1,thus inhibiting the progression of osteoarthritis.It provided new possibilities for OA treatment.This paper will review the research progress of IL-1Ra in the treatment of osteoarthritis,and summarize the related pathways mediated by IL-1Ra and its mechanism and strategy for the treatment of osteoarthritis,so as to provide reference for research and clinical development of osteoarthritis treatment.

关 键 词：白介素1 白介素1受体拮抗剂 骨关节炎 

分 类 号：R684.3[医药卫生—骨科学]